Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Market: Pharmaceuticals and Healthcare

Asia Pacific, 176 pages report, published by GBI Research

Report ThumbnailAugust-2016
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Summary

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs

Read More
  • 1.2 List of Figures
  • Figure 1: T2DM Therapeutics Market, South-East Asia, Heat Map for Marketed Products, 2016 70
  • Figure 2: T2DM Therapeutics Market, South-East Asia, Heat Map for Marketed Products, 2016 (continued) 71
  • Figure 3: T2DM Therapeutics Market, Global, Pipeline, 2016 73
  • Figure 4: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2016 75
  • Figure 5: T2DM Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 76
  • Figure 6: T2DM Therapeutics Mar
Read More
  • 1.1 List of Tables
  • Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy 26
  • Table 2: T2DM Therapeutics, Global, All Pipeline Products, Discovery Stage, March 2016 138
  • Table 3: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Stage, March 2016 141
  • Table 4: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Stage, March 2016 149
  • Table 5: T2DM Therapeutics, Global, All Pipeline Products,
Read More
  • 1 Table of Contents
  • 1 Table of Contents 4
  • 1.1 List of Tables 7
  • 1.2 List of Figures 7
  • 2 Introduction 10
  • 2.1 Disease Introduction 10
  • 2.2 Epidemiology 10
  • 2.3 Symptoms 11
  • 2.4 Etiology and Pathophysiology 11
  • 2.5 Diagnosis 14
  • 2.6 Classification 15
  • 2.7 Prognosis 15
  • 2.8 Treatment Options 16
  • 2.8.1 Treatment Algorithm 16
  • 2.8.2 Non-insulin T2DM Therapies 18
  • 2.8.3 Insulin T2DM Therapies 21
  • 2.9 Treatment Segments 22
  • 2.9.1 Non-insulin therapies 23
  • 2.9.2 Insulin Therapies 38
  • 2.10 Co-morbidities and Complicatio
Read More
  • Newer Therapies Will Steer Type 2 Diabetes Market in South-East Asia to $2.7 Billion by 2022, says GBI Research

    The South-East Asian Type 2 Diabetes Mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.7 billion in 2015 to $2.7 billion by 2022, at a compound annual growth rate of 7.1%, according to business intelligence provider GBI Research.

    The company’s latest report* states that as well as the r
Read More

Related Products

GBI ResearchType 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust GrowthProduct ThumbnailType 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth, Industry ReportProduct #: 541138
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2020 Global Market Analyst. All Rights Reserved